Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › NSCLC

NSCLC

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for NSCLC

25 trials tracked for NSCLC: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 108 citations.

25Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 17 Phase 1 3 Other / NA 2
  1. Phase 3 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) Completed · 108 cited
  2. Phase 3 Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC Completed · 36 cited
  3. Phase 3 Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) Completed
  4. Phase 2 Afatinib in NSCLC With HER2 Mutation Completed
  5. Phase 2 Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Completed
  6. Phase 2 A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) Completed
Show 19 more trials
  1. Phase 2 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer Completed
  2. Phase 2 Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer Completed
  3. Phase 2 A Rollover Protocol of Dacomitinib For Patients In Japan Completed
  4. Phase 2 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) Completed
  5. Phase 2 Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC Completed
  6. Phase 2 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Completed
  7. Phase 2 Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Completed
  8. Phase 2 Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy Completed
  9. Phase 2 Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC Completed
  10. Phase 2 Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Completed
  11. Phase 2 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Completed
  12. Phase 2 Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) Completed
  13. Phase 2 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Completed
  14. Phase 2 Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer Completed
  15. Phase 1 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Completed
  16. Phase 1 A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors Completed
  17. Phase 1 A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors Completed
  18. N/A Descriptive Observational Study ALK-2016-CPHG Completed
  19. N/A EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

NSCLC: what the trials found

Durvalumab has demonstrated a favorable safety profile in clinical trials, with zero participants experiencing Grade 3 or Grade 4 clinical laboratory toxicities in specific cohorts 13. Additionally, Durvalumab was evaluated in other established studies 10.

Erlotinib showed a 3-year survival rate of 37% to 41% in patients 3. Other established interventions include immune checkpoint inhibitors combined with docetaxel 1 and bevacizumab in combination with paclitaxel/carboplatin 2.

Recent results — preliminary, needs further review

  • Osimertinib showed progression-free system (PFS) rates at 18 months of 51.1%, 67.2%, and 53.5% 4.
  • E-602 was evaluated in a Phase 2 trial 5.

For the clinician treating this condition

  • Durvalumab is associated with low rates of high-grade clinical laboratory toxicities 13.
  • Erlotinib has established survival data for long-term outcomes 3.
  • Osimertinib shows varying progression-free rates at the 18-month mark 4.

AI synthesis of 7 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Local ablative therapy integrated with first-line EGFR TKI improves progression-free survival and overall survival
Pulmonology & Critical Care Meta-analysis
Local ablative therapy integrated with first-line EGFR TKI improves progression-free survival and overall survival Adding local treatment to lung cancer drugs improves survival
This systematic review and meta-analysis of 31 studies indicates that integrating local ablative therapy (LAT) with first-line EGFR tyrosine…
Combining local ablative therapy with targeted drugs may help patients with specific lung cancer mutations live longer.
Aug 5, 2026
Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits
Allergy & Immunology Meta-analysis
Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits New Treatment Combinations Show Promise for Advanced Lung Cancer
This systematic review and meta-analysis of 3,606 patients evaluated 8 treatment strategies for advanced EGFR-mutant NSCLC. The analysis fou…
Specific drug combinations, including ivonescimab and amivantamab, show potential benefits for patients with advanced EGFR-mutant lung cance…
Frontiers Jul 31, 2026
Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41)
Oncology Phase III
Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41) Alectinib Shows Better Progression-Free Survival Than Crizotinib for NSCLC
This pooled analysis of Phase III trials involving 500 patients with ALK-positive NSCLC found that alectinib significantly improved progress…
Alectinib showed better progression-free survival than crizotinib in a study of 500 patients with ALK-positive lung cancer.
Jul 27, 2026
Robotic-assisted thoracoscopic segmentectomy increases lymph node stations examined and reduces hospital stay duration
Oncology Meta-analysis
Robotic-assisted thoracoscopic segmentectomy increases lymph node stations examined and reduces hospital stay duration Robotic surgery may help lung cancer patients stay in hospital less
This meta-analysis of 19,805 patients with early-stage NSCLC compares robotic-assisted thoracoscopic segmentectomy (RATS) to video-assisted …
A large review suggests robotic-assisted surgery for early-stage lung cancer can lead to more lymph node checks and shorter hospital stays.
Jul 21, 2026
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
Oncology Cohort
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer CT scans may help predict lung cancer treatment response
This cohort study utilized a CT-based immune radiomic signature, known as CT-RadScore, across multiple patient cohorts including TCIA, TCGA,…
A new way to analyze CT scans could help doctors predict how lung cancer patients respond to immunotherapy and other drugs.
Frontiers Apr 30, 2026
Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
Pulmonology & Critical Care RCT
Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC Does adding targeted radiation to immunotherapy help advanced lung cancer?
A phase 2 randomized trial in 50 adults with metastatic NSCLC found no significant difference in 6-month progression-free survival (49% vs 4…
Adding high-dose radiation to immunotherapy did not improve outcomes or reduce side effects for advanced lung cancer patients who had alread…
Apr 2, 2026

Questions about NSCLC

Does robotic surgery reduce hospital stays for patients with early-stage NSCLC?

Yes, robotic surgery (RATS) for early-stage NSCLC is linked to shorter hospital stays compared to VATS, though evidence is mixed.

Full answer →